24/7 Wall St. has put together a preview of some of the major companies reporting their quarterly results this week. We have included the consensus earnings estimates from Thomson Reuters and the stock price and trading history, as well as added some additional color on each. Be advised that the earnings and revenue estimates may change ahead of the formal reports, and some companies may change reporting dates as well.

Ambarella

Ambarella Inc. (NASDAQ: AMBA) will share its most recent quarterly results on Tuesday. The consensus estimates call for earnings per share (EPS) of $0.81 and $81.73 million in revenue.

Canaccord Genuity recently reiterated a Buy rating and raised its price target to $120 from $115. The firm sees the drone market roughly doubling each of the next couple years, including non-flying, but camera-capable drones. With trends moving quickly to include drone-specific cameras, versus only mounting a sports camera such as GoPro. Ambarella drone camera revenue is expected to grow to near $30 million in fiscal 2016 and $50 million in fiscal 2017 from roughly $6 million in fiscal 2015 given close partnership with market leader DJI.

Shares were at $96.31 at the close on Friday, in a 52-week trading range of $32.50 to $129.19. The stock has a consensus analyst price target of $105.45.

ALSO READ: 7 Analyst Stocks Under $10 With Massive Upside

Dollar Tree

Dollar Tree Inc. (NASDAQ: DLTR) is scheduled to reveal its fiscal second-quarter results on Tuesday morning. The consensus estimates call for $0.62 in EPS, as well as $3.04 billion in revenue.

Within the industry, Dollar Tree offers among the highest top-line growth in mid/large-cap retail, and a differentiated fixed price concept with significantly lower prices than anyone in the channel, according to Wells Fargo. The investment bank still sees room for continued top-line momentum and expects gross margins to stabilize.

Shares were trading at $76.73 on Friday’s close. The consensus price target is $85.77. The stock has a 52-week trading range of $53.33 to $84.22.

Ciena

Ciena Corp. (NASDAQ: COST) is set to report its fiscal second-quarter results before Thursday’s opening bell. The analysts’ consensus estimates call for EPS of $0.34 and $629.8 million in revenue.

Ciena is expected to get a large chunk of the Verizon 100 Gbps Dense Wave Division Multiplex Metro optical network build-out. Some Wall Street analysts thinking it could see as much as 30% of the total and that Verizon could end up being as much as a 10% customer next year. In addition, some analysts feel that the company can hit 45% gross margins and low to mid-teens operating margins over the next two to three years.

Shares were changing hands at $22.86 on Friday’s close. The consensus price target is $27.96, and the stock has a 52-week trading range of $13.77 to $26.50.

ALSO READ: 5 Companies Receiving Multiple Fresh Analyst Upgrades

Campbell Soup

Campbell Soup Co. (NYSE: CPB) is scheduled to report its fiscal fourth-quarter results early on Thursday. The consensus analyst estimates call for $0.42 in EPS and revenue of $1.69 billion.

Back in July the company offered up new guidance to investors about its financial strategies. Along this vein, the company unveiled plans for its new divisions. CEO Denise Morrison updated investors on Campbell’s strategies to improve its financial performance. Ultimately the goals were to be more transparent about how its foods and drinks are made to build greater consumer trust and to increase the company’s focus on faster-growing categories and regions.

Shares of Campbell ended the week at $47.80. The consensus price target is $46.27. The 52-week trading range is $41.15 to $50.80.

Medtronic

Medtronic PLC (NYSE: MDT) also is set to share its latest quarterly earnings Thursday morning. The consensus analyst estimates call for $1.01 in EPS and $7.05 billion in revenue.

The company is now based in Ireland after the gigantic merger with Covidien, which many on Wall Street see as historic, probably one of the largest in the medtech industry. The merger led to the creation of a unique company that combines the extensive and innovative abilities of both Medtronic and Covidien. It has over 85,000 employees in more than 160 countries and annual revenues of $27.4 billion in 2014. Medtronic’s three fundamental strategies are therapy innovation, globalization and economic value.

Shares closed at $73.56 on Friday, in a 52-week trading range of $55.54 to $79.50. The stock has a consensus analyst price target of $87.03.

ALSO READ: 5 Stocks Warren Buffett Likely Bought More of During the Sell-Off

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.